The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.

First LinkedIn, now Yahoo, the exodus of global tech giants from China indicates a toughening regulatory environment over personal data collection, storage and use with implications for pharma. Buckle up for a bumpy ride, experts say.

In this week's podcast edition of Five Must-Know Things: Pfizer’s mixed Q3; delayed US approval for Janssen/Legend’s CAR-T; promising new data in RSV; Dr Reddy’s lays out more COVID product plans; and experts dissect decentralized trials.

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker